UPSIDE Foods’ $400 million financing was a Series C round announced on April 21, 2022—not a new 2026 raise. The money was intended to move cultivated chicken from pilot production toward commercial manufacturing, including a large facility, product development, partnerships, regulatory work and supply-chain investment. It was a major commercialization bet, but it did not by itself deliver cheap, nationwide cultivated meat.
What UPSIDE Foods actually announced
UPSIDE Foods, formerly Memphis Meats, said it had raised $400 million in Series C financing on April 21, 2022. The company described it as the largest cultivated-meat funding round at that time. TechCrunch reported that the round brought UPSIDE’s total capital raised to approximately $608 million.
The company is based in Berkeley, California, and was developing production beyond its Emeryville production and innovation center. Its objective was to make chicken from animal cells rather than raise and slaughter a chicken for every batch.
The original announcement anticipated a commercial launch later in 2022, subject to regulatory review and operational readiness. That timing should be read as a plan, not evidence that broad consumer availability had already been achieved.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minute#1 Best Overall
UPSIDE’s Series C announcement and TechCrunch’s contemporaneous coverage provide the financing details.
Why the investor mix mattered
UPSIDE’s disclosed backers spanned sovereign funds, food-industry companies, technology investors and prominent individual investors:
- Temasek
- Abu Dhabi Growth Fund
- Cargill
- Givaudan
- Tyson Foods
- Bill Gates
- John Doerr
- Kimbal Musk and Christiana Musk
- Baillie Gifford
- Cercano Management
- CPT Capital
- Norwest Venture Partners
- SALT Fund
- SoftBank Vision Fund 2
- SOSV’s Indie Bio
- Synthesis Capital
The mix signaled that cultivated meat was being treated as a potential food-manufacturing and food-security industry, not only as a laboratory project. Strategic investors such as Cargill, Givaudan and Tyson could gain insight into a future protein category; sovereign and growth investors could be seeking long-horizon exposure to industrial biotechnology. Their participation did not mean every investor endorsed identical environmental, technical or financial assumptions.
What the $400 million was supposed to fund
UPSIDE said the financing would support five connected parts of commercialization:
Free tools Windows power users keep installed
One-click scans. No signup required.
- Product innovation: improving cultivated-chicken formats and the ingredients used to turn cell material into food.
- Partnerships: working with food, ingredient and distribution companies as products moved beyond the laboratory.
- Production infrastructure: expanding the controlled equipment and quality systems needed for food manufacturing.
- A commercial-scale facility: building capacity aimed at tens of millions of pounds annually, according to the company’s target.
- Inputs and supply chains: developing reliable sources of cell-culture media and other materials.
TechCrunch reported an estimated 18-to-24-month construction period for a commercial facility and described a transition from technology developed at UPSIDE’s EPIC facility. That was a historical estimate, not a guarantee of completion, validated output or profitable operation.
Rank #2
How UPSIDE’s cultivated chicken is made
Cultivated meat is made from animal cells. It is therefore different from plant-based meat, even if plant ingredients may appear in a finished recipe.
- Starting cells: UPSIDE says cells were originally taken from a heritage-breed chicken egg.
- Cell bank: Selected cells are stored in a master cell bank so future production can begin from a consistent source.
- Expansion: Cells grow in cultivators—controlled tanks that perform a broad role comparable to brewery vessels.
- Nutrients: The cells receive water, sugars, amino acids, vitamins, minerals and other nutrients.
- Harvest and formulation: The resulting cell material is processed into chicken products, with additional ingredients used for the desired texture and format.
UPSIDE says the process takes roughly three weeks from cells to cultivated chicken. That figure describes the company’s stated process timeline; it does not mean a complete chicken muscle is simply grown in a tank. Industrial production also has to manage cell growth, oxygen transfer, mixing, tissue structure, harvesting, food safety and downstream processing.
The process can reduce the need to raise and slaughter chickens for each production batch, but calling the product absolutely “animal-free” would be inaccurate: it begins with animal cells.
What the FDA milestone established—and what it did not
On November 16, 2022, the FDA said it had completed its first voluntary pre-market consultation for human food made with animal-cell-culture technology. The review covered UPSIDE’s cell lines and cell banks, manufacturing controls, production inputs and cultured-cell material.
FDA said it had no further questions about UPSIDE’s safety conclusion at that stage. That is a meaningful regulatory milestone, but FDA explicitly said a pre-market consultation is not an approval process. USDA’s Food Safety and Inspection Service (USDA-FSIS) still had to address applicable inspection and meat-regulation requirements before market entry.
FDA’s inventory identifies the consultation as:
| Item | Record |
|---|---|
| Product category | Cultured chicken cell material |
| Species | Gallus gallus |
| Sponsor | UPSIDE Foods |
| Consultation number | CCC 002 |
| FDA response date | November 16, 2022 |
See the FDA announcement and the CCC 002 record.
A November 14, 2024 FDA supplement response continued to report no questions about the safety conclusion for food made under the defined process. It also discussed heavy-metal specifications and future process changes. The document said UPSIDE was then producing cultured chicken cell material with serum-containing media and had not notified FDA that it had begun using serum-free media. A response about a defined process does not automatically cover every future formulation, facility or process modification.
Rubicon and the scale question
UPSIDE later announced Rubicon, a planned cultivated-meat facility in the Chicagoland area. The company said Rubicon would initially make ground cultivated-chicken products, begin at capacity in the millions of pounds and potentially expand to as much as 30 million pounds. UPSIDE also described more than $140 million in regional investment and more than 75 planned jobs.
Those figures are announced plans and nameplate targets, not independently verified production. A facility can have a theoretical capacity while construction, equipment qualification, inspection, process validation, staffing or demand limit actual output. The Rubicon announcement does not establish that the full 30-million-pound capacity was operating by August 2026.
What happened after the financing
The clearest later milestone was regulatory, not immediate supermarket scale. As of August 18, 2026, UPSIDE’s public website says its chicken is available through restaurant partners while the company continues working toward broader production and everyday pricing.
That status is materially different from nationwide grocery distribution. The available evidence does not establish nationwide retail availability, full Rubicon utilization, current unit economics or output at the announced capacity.
FDA’s public inventory page, updated February 19, 2026, listed five completed animal-cell-culture consultations, including UPSIDE, GOOD Meat, Believer, Wildtype and Mission Barns. A growing consultation list shows regulatory activity; it does not show that every company has reached cost parity or mass distribution.
Recommended Free Tools
The commercialization scorecard
The financing should be judged against the practical hurdles that determine whether cultivated meat becomes a durable food business.
| Test | What success requires | UPSIDE position supported by the available record |
|---|---|---|
| Regulation | FDA consultation, USDA-FSIS inspection, compliant facilities and labeling | FDA completed consultation CCC 002 and had no further questions about the defined safety conclusion; the consultation itself was not approval. |
| Production scale | Reliable cell density, oxygen transfer, batch consistency, throughput and validated equipment | Commercial facilities and capacities were announced, but delivered output and utilization are not established here. |
| Cost | Affordable media, facilities, labor, utilities, quality systems and downstream processing | No evidence here proves price parity with conventional poultry. |
| Product quality | Acceptable taste, texture, cooking behavior, nutrition and format | Restaurant-partner availability indicates a controlled launch path; broad repeat-purchase performance is not established. |
| Consumer adoption | Trial, repeat purchase, willingness to pay and trust | Public access through restaurant partners is narrower than mass-market adoption. |
The main economic and operational risks
Scale-up can change the process
Results in small vessels do not automatically transfer to large tanks. Mixing, oxygen transfer, heat control, contamination prevention and cell behavior can all affect yield and consistency as volume increases.
Growth media can dominate cost
Nutrients, supplements and other media inputs must become economical at food volumes. Even a technically successful process can fail as a commodity business if media, sterile manufacturing or quality controls remain too expensive.
Construction and validation take time
Building a facility is only one step. Equipment must be qualified, processes validated, inspections completed and production teams trained before nameplate capacity becomes dependable supply.
Best Value
Premium launches do not prove poultry-scale economics
Restaurants can offer controlled menus and help introduce a new product. They do not demonstrate that cultivated chicken can match the price, volume and availability of a highly optimized conventional-poultry supply chain.
Environmental performance depends on execution
UPSIDE’s website cites potential reductions of up to 90% in land and water use and greenhouse-gas emissions based on a cited study. Those are not guaranteed UPSIDE-specific results. Actual lifecycle performance depends on electricity, media inputs, facility efficiency, yield, waste and downstream processing.
Consumer and policy responses remain variables
People may differ in their reactions to cultivated-food terminology, perceived naturalness, labeling and production methods. Regulatory, labeling and state-policy requirements can also affect market access and should be assessed for the relevant jurisdiction and date.
How to interpret the $400 million today
The round supplied capital and credibility for an exceptionally capital-intensive transition: from cell biology to regulated food manufacturing. It helped fund infrastructure and kept UPSIDE moving toward commercial sales, but investor confidence was not proof of profitability, price parity, mass production or consumer acceptance.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →The strongest current conclusion is narrower: UPSIDE progressed from a laboratory-stage company to a regulated, restaurant-facing cultivated-chicken operation, while the hardest questions—repeatable large-scale output, costs, facility execution and broad demand—remain the tests of whether the original financing created a viable category.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
